Evidence map›Paper›PMID 24976815›Full record

ArticleCurrent hypertension reviews2012

Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?

Xiang Wang, Ana-Maria Bosonea, Jeffrey Odenbach, Carlos Fernandez-Patron

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current hypertension reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xiang WangDepartment of Biochemistry (XW, A-MB, JO, CF-P), School of Translational Medicine (XW, A-MB, JO, CF-P) and the Cardiovascular Research Group (XW, A-MB, JO, CF-P), Mazankowski Alberta Heart Institute (CF-P), University of Alberta, Edmonton, AB, Canada.
Ana-Maria BosoneaDepartment of Biochemistry (XW, A-MB, JO, CF-P), School of Translational Medicine (XW, A-MB, JO, CF-P) and the Cardiovascular Research Group (XW, A-MB, JO, CF-P), Mazankowski Alberta Heart Institute (CF-P), University of Alberta, Edmonton, AB, Canada.
Jeffrey OdenbachDepartment of Biochemistry (XW, A-MB, JO, CF-P), School of Translational Medicine (XW, A-MB, JO, CF-P) and the Cardiovascular Research Group (XW, A-MB, JO, CF-P), Mazankowski Alberta Heart Institute (CF-P), University of Alberta, Edmonton, AB, Canada.
Carlos Fernandez-PatronDepartment of Biochemistry (XW, A-MB, JO, CF-P), School of Translational Medicine (XW, A-MB, JO, CF-P) and the Cardiovascular Research Group (XW, A-MB, JO, CF-P), Mazankowski Alberta Heart Institute (CF-P), University of Alberta, Edmonton, AB, Canada.
University of Alberta · CA

Funding

CIHR 106580-1PHS HHS 106580-1
6 · The paper itself

Abstract

Hypertension, the condition characterized by sustained elevated blood pressure, affects over 25% of adults in developed countries and is accompanied by pathological cardiac remodeling (

Indexed as

cardiovascular fibrosiscardiovascular hypertrophyG protein-coupled receptorshypertensionmetalloproteinasessignaling pathways

Identifiers

PMID24976815
PMCPMC4071059
OpenAlexW2105549969

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.